Gapping down
In reaction to earnings/guidance:
- NOK -15.1%, INOV -11.7%, APRN -10.2%, BLKB -6.5%, INSM -6.2%, CS -5.9%, ABMD -5.3%, EBAY -5%, EQNR -4.2%, PEGA -4%, WCN -3.9%, SPOT -3.9%, PI -3.8%, LVGO -3.5%, WEX -3.4%, TDOC -3.3%, CREE -3.2%, ACA -3.1%, MSA -2.9%, ETSY -2.6%, CHD -2.5%, OESX -2.5%, WERN -2.2%, RYN -2.1%, NTB -2%, MUSA -1.9%, FIS -1.9%, SNY -1.8%, FBHS -1.7%, PBFX -1.7%, SFM -1.6%, AXS -1.4%, PLX -1.4%, APO -1.3%, CERN -1.1%
M&A news:
- MRVL -7.7% (Inphi confirms agreement to be acquire by Marvell; MRVL also provides Q3 guidance)
Other news:
- TCDA -30.5% (provides update on FDA interactions pertaining to veverimer)
- CCXI -12.9% (announces positive topline data from AURORA trial of avacopan)
- ARCH -5.2% (convertible offering)
- WCN -3.9% (increases dividend)
- MUSA -1.9% (announces update to its capital allocation strategy; initiates $0.25/sh dividend)
- RARE -1.6% (prices offering of 4,444,444 shares of its common stock at $90.00 per share)
Analyst comments:
- FSLR -1.4% (downgraded to Neutral from Overweight at JP Morgan)